Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Takeda
Celgene
Incyte Corporation
NextCure, Inc.
Acerta Pharma BV
Servier
CRISPR Therapeutics
Incyte Corporation
AbbVie
Bristol-Myers Squibb
Bristol-Myers Squibb
Celgene
Celgene
Amgen
Pharmacyclics LLC.
BeiGene
GlaxoSmithKline
OrphAI Therapeutics
Celgene
Daiichi Sankyo
Ono Pharmaceutical Co., Ltd.
Amgen
Kyowa Kirin Co., Ltd.
Amgen
Amgen
Arog Pharmaceuticals, Inc.
MacroGenics
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Intellia Therapeutics
Pfizer
Jazz Pharmaceuticals
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Bristol-Myers Squibb
Bristol-Myers Squibb
Novartis
Eli Lilly and Company
AbbVie
Molecular Templates, Inc.
BeiGene
Takeda
Sanofi
Alexion Pharmaceuticals, Inc.
Sanofi
ERYtech Pharma
Pfizer
Bristol-Myers Squibb
Incyte Corporation
Takeda